Drugs / ST266
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04720378 | May 2021 → May 2022 | cytokine release syndrome | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03901781 | Oct 2019 → May 2022 | ocular hypertension | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02369861 | Mar → Oct 2015 | dry eye syndrome | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01714973 | Oct 2012 → Jul 2015 | radiodermatitis | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06315738 | Aug 2024 → Jun 2029 expected | necrotizing enterocolitis | Noveome Biotherapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00886470 | Jun 2009 → Mar 2010 | — | Noveome Biotherapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 23 trials | ||||||
| Phase 2 | NCT05066698 | Apr → Sep 2022 | corneal disorder | Noveome Biotherapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03687632 | Jun 2019 → Aug 2020 | corneal disorder | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01715012 | Oct 2012 → Jan 2015 | diabetes mellitus | Noveome Biotherapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02978183 Comparator | Dec 2016 → Feb 2017 | conjunctivitis | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02761993 Comparator | Apr 2016 → Oct 2017 | periodontitis | Noveome Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02389777 Comparator | Mar → Aug 2015 | sunburn | Noveome Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST266 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02978183 ↗ |
| Modality | Protein / enzyme biologic | “ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution.” NCT00886470 ↗ |
| Route | Topical | “Topical treatment every other day” NCT00886470 ↗ |